Movement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review

Market Focus06-05

On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.

On the news front, the company announced on June 4 that the new drug application for KJ103 for injection was accepted by China's National Medical Products Administration, designated for desensitization therapy in highly sensitized kidney transplant patients. The product was granted priority review status on May 20. KJ103 is a global first-in-class low-immunogenicity IgG-degrading enzyme. Phase III clinical data demonstrated a 100% pre-transplant desensitization success rate and 100% kidney transplant success rate, with graft survival exceeding 100% at three months.

The broader biotechnology sector also showed recovery today, with AKESO up 2.87%, Innovent Biologics up 3.66%, SKB Bio up 7.28%, and Remegen up 2.07%, providing additional tailwind for individual stock performance following prior sector-wide weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185904720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185904720","market":"us","top_or_hot":-1,"title":"Movement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review","media":"Market Focus","content":"<p><p>On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.</p><p>On the news front, the company announced on June 4 that the new drug application for KJ103 for injection was accepted by China's National Medical Products Administration, designated for desensitization therapy in highly sensitized kidney transplant patients. The product was granted priority review status on May 20. KJ103 is a global first-in-class low-immunogenicity IgG-degrading enzyme. Phase III clinical data demonstrated a 100% pre-transplant desensitization success rate and 100% kidney transplant success rate, with graft survival exceeding 100% at three months.</p><p>The broader biotechnology sector also showed recovery today, with AKESO up 2.87%, Innovent Biologics up 3.66%, SKB Bio up 7.28%, and Remegen up 2.07%, providing additional tailwind for individual stock performance following prior sector-wide weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.</p><p>On the news front, the company announced on June 4 that the new drug application for KJ103 for injection was accepted by China's National Medical Products Administration, designated for desensitization therapy in highly sensitized kidney transplant patients. The product was granted priority review status on May 20. KJ103 is a global first-in-class low-immunogenicity IgG-degrading enzyme. Phase III clinical data demonstrated a 100% pre-transplant desensitization success rate and 100% kidney transplant success rate, with graft survival exceeding 100% at three months.</p><p>The broader biotechnology sector also showed recovery today, with AKESO up 2.87%, Innovent Biologics up 3.66%, SKB Bio up 7.28%, and Remegen up 2.07%, providing additional tailwind for individual stock performance following prior sector-wide weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1185904720","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185904720","pubTimestamp":1780623753,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.On the news front, the company announced on June 4 that the new...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"动静快讯|宝药业-B常规交易涨5.59%核心管线KJ103 NDA获NMPA优先审评受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.On the news front, the company announced on June 4 that the new drug application for KJ103 for injection was accepted by China's National Medical Products Administration, designated for desensitization therapy in highly sensitized kidney transplant patients. The product was granted priority review status on May 20. KJ103 is a global first-in-class low-immunogenicity IgG-degrading enzyme. Phase III clinical data demonstrated a 100% pre-transplant desensitization success rate and 100% kidney transplant success rate, with graft survival exceeding 100% at three months.The broader biotechnology sector also showed recovery today, with AKESO up 2.87%, Innovent Biologics up 3.66%, SKB Bio up 7.28%, and Remegen up 2.07%, providing additional tailwind for individual stock performance following prior sector-wide weakness.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185904720","isCrawlerRequest":true}